Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective validation of a thiopurine hepatotoxicity prediction algorithm in adults with inflammatory bowel disease
NL-OMON42663Active, not recruiting
- Sponsor
- Zuyderland
- Start
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of azathioprine and mercaptopurine in inflammatory bowel disease (IBD), Crohn's disease, autoimmune colitis and 1 more, sponsored by Zuyderland. Primary endpoints: Hepatotoxicity and Week-1 6-MMPR level. Started Dec 2015; status: active, not recruiting.
02
Drugs
azathioprinemercaptopurine
03
Conditions
inflammatory bowel disease (IBD)Crohn's diseaseautoimmune colitisindeterminate colitis (IC)
Beyond the preview
Go deeper on NL-OMON42663.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42663.